Navigation Links
Unmet expectations and smoking prove key factors in quitting bladder medication
Date:5/13/2010

Nine out of ten patients who discontinued their overactive bladder (OAB) medication said it was because it didn't work as expected or they couldn't tolerate it, according to research in the May issue of the urology journal BJUI.

US researchers also discovered that smokers, men with enlarged prostates and people with bladder infections are also significantly more likely to stop taking prescription drugs for bladder problems.

The team surveyed 6,577 adults who said in a National Family Opinion survey that they had been prescribed medication for OAB in the last 12 months and 82% responded.

They found that patients who had abandoned their medication were much more likely to be bothered by OAB symptoms than those who had persisted and more likely to have had a diagnosis for a condition such as OAB or incontinence.

A quarter of the 5,392 who responded had discontinued one or more of their OAB drugs in the last year, with the majority giving multiple reasons. Just under half (46%) said the medication didn't work as expected, 23% learnt to get by without medication and 21% reported side effects. Other reasons included cost, change of insurance status, not wanting to use medication, advice from healthcare professionals and health improvements. A quarter said they had switched to a new medication.

"Encouraging people with long-term health conditions to persist with medication is common and problematic" says Professor Linda Brubaker from Loyola University, Chicago, who co-authored the paper with urology colleagues from across the USA.

"Recent database studies suggest that the number of OAB patients who stop taking their medication is much higher than clinical trials would suggest.

"It is important to identify why people stop taking their medication as persistence with medication is generally associated with positive health outcomes and reductions in healthcare resource use and costs."

Key findings of the study included:

  • Bothersome OAB symptoms were reported more frequently by patients who had discontinued their medication: 10% more were "quite a bit more" bothered about needing to urinate at night, 13% more with urgency, 9% more with incontinence and 11% more with frequency.

  • More patients in the discontinued medication group had a medical diagnosis of OAB (10% more than the group who persisted), incontinence (8% more), bladder infection (6% more) and urinary retention (4% more).

  • There were no statistically significant differences in sex, age or race, household income, health insurance and prescription insurance between the two groups and relatively minor differences when it came to beliefs about OAB, including what was normal and how it could be treated.

  • A third of the people who had discontinued gave one reason for stopping, a third gave two reasons and a third gave three reasons.

A second paper in the May issue of BJUI focuses on the results of a six-month follow-up on the patients who were still taking their medication at the time of the above study, based on an 84% response rate.

This showed that 66% were still taking their medication, 18% had discontinued and 17% had switched medication in the intervening six months.

Researchers found that a number of factors increased the chances of patients discontinuing their OAB medication, including:

  • Being a current smoker (up 80%)
  • Having an enlarged prostate (up 74%) or a bladder infection (up 54%).
  • Believing that bladder medication caused severe side effects (up 111%) or not knowing whether it did or not (up 76%).
  • Being bothered "quite a bit more" by a sudden urge to urinate with little or no warning (up 54%).

However, being on multiple prescriptions or having had an episode of incontinence in the last week increased the odds of compliance.

"To our knowledge this is the first study to ask patients why they discontinued their OAB medication" says Professor Brubaker. "We believe that our findings point to the need for healthcare providers to foster realistic expectations about how effective OAB treatment will be and about any side effects.

"We also believe that healthcare providers should discuss lifestyle changes, such as smoking cessation, urgency control strategies and pelvic floor muscle training with OAB patients. Research has shown that providing behavioural advice as well as drugs to patients with OAB can improve both symptoms and satisfaction with treatment."


'/>"/>

Contact: Annette Whibley
wizard.media@virgin.net
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Number of Children in Foster Care Decreases but Critical Needs Go Unmet
2. Tahitian Noni Extra Sales Exceed Expectations
3. Knee Surgeons Expectations May Differ From Yours
4. Patient and doctor expectations from joint replacement surgeries not always aligned
5. Does Mom Need Help to Stop Smoking?
6. Smoking While Pregnant May Raise Psychiatric Risks in Kids
7. Exposure to prenatal smoking may lead to psychiatric problems
8. Smoking Ups Risk of Second Breast Cancer
9. Smoking May Be in Your Genes
10. Tailored Therapy May Help More Stop Smoking
11. Weight Gain, Smoking May Make Prostate Cancer Deadlier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology: